Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy

Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after... AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Loading next page...
 
/lp/springer-journals/amrubicin-monotherapy-for-patients-with-extrapulmonary-neuroendocrine-5ss1JO6c6l

References (23)

Publisher
Springer Journals
Copyright
Copyright © 2015 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-015-2706-y
pmid
25702050
Publisher site
See Article on Publisher Site

Abstract

AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.

Journal

Cancer Chemotherapy and PharmacologySpringer Journals

Published: Apr 1, 2015

There are no references for this article.